Articles On Prescient Therapeutics (ASX:PTX)

Prescient Therapeutics Limited (ASX: PTX) develops personalised medicine approaches to address mutations that cause cancer. The Company employs a targeted therapy approach to target individual tumour variability rather than the conventional...

Clinical-stage Oncology Company, Prescient Therapeutics Limited (ASX: PTX), that develops personalised medicine approaches to address mutations causing cancer. Prescient’s deep product pipeline include 2 clinical stage drugs with multiple s...

Shares in Prescient Therapeutics Limited (ASX:PTX) surged 50% on Wednesday after the clinical stage oncology company developing personalised medicine approaches to cancer released promising news in relation to its Phase 1b study in patients...

Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute myeloid leukemia (AML) after three patients were completely eradicated of the disease. The clinical stage company had been treati...

For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Prescient Therapeutics Limited (ASX: PTX) is involved in the development of breakthrough personalised cancer therapies via its novel anti-cancer drug candidates, PTX-100 and PTX-200, that have shown great promise in the treatment of a range...

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in small molecule drug development focused on new cancer drugs. The company is known for having a robust clinical pipeline with two drug candida...

Oncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboration with Adelaide-based Carina Biotech to develop new Chimeric Antigen Receptor T-cell (CAR-T) targeted cell therapies to combat solid tumours...

HeraMED’s (ASX:HMD) foetal ultrasound heart rate monitor has got its long awaited green light to enter the US market and it has doubled in just a few days. The US Food and Drug Administration has approved its 510(k) application meaning it c...

Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne. In this episode Tim chats with Steven Yatomi-Clarke, CEO and managing director of Prescient Therapeutics (ASX:PTX...

With a focus on addressing mutations causing cancer, Prescient Therapeutics Limited (ASX: PTX) develops personalised medicines as potential novel cancer remedies targeting an array of debilitating cancers with significant unmet need.  Presc...

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel targeted cancer therapies for a range of challenging cancers with significant unmet need. Prescie...

To stay updated with PTX company activities and announcements, please update your details on their investor centre. Join Our Discussion Start discussion with value Investors for ASX Stock Market Investment and Opinion. 6 Cannabis Stoc...

“History is bunk!’’ declared industrialist Henry Ford, but unfortunately for the oro-mucosal delivery specialist Suda, distancing itself from its corporate past has not been a simple case of cranking up the Model T and hitting the road. In...

Australian-headquartered global pharmaceutical leader, SUDA Pharmaceuticals Limited (ASX: SUD) is engaged in the reformulation of existing drugs and provision of medication via the oral mucosa. The company uses its exclusive OroMist® techno...

Yesterday, Trevor Hoey looked at the turnaround in the health services sector. He pointed out that the S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start o...

In light of the volatility that has rocked global equities markets including the ASX, Finfeed felt it was timely to assess the damage on a sector by sector basis. What’s more, we have come up with six stocks that appear to have plenty going...

Drugs intake in the form of pills, capsules, and tablets are not the most efficient ways of taking medicine, because only about 25% of the drug reaches where it should. Several factors including food affect, enzymatic degradation, drug meta...

Imugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focusses on the development of emerging immunotherapies to enhance the efficacy of cancer treatments. The company utilises its unique platform t...

Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on th...

Clinical stage oncology company, Prescient Therapeutics Limited (ASX: PTX) is engaged in developing personalised medicines to treat a range of challenging cancers. The company is known for having one of the deepest clinical pipelines on ASX...

An oro-mucosal drug delivery company headquartered in Perth, SUDA Pharmaceuticals Ltd (ASX: SUD) uses its OroMist® technology for the development of low-risk oral sprays. The company reformulates the existing pharmaceuticals into an oral sp...

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company that works on mutation causing cancer. The existing product portfolio of the company includes two drug candidates, PTX 100 and PTX 200, under the development pha...

Clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of developing a breakthrough to traditional therapies by its novel drug candidates that have shown great promise in the treatment of a range of canc...

On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in patients with multiple cancers. The trial would reportedly be led by one of the wor...

Australian company Prescient Therapeutics (ASX:PTX), a clinical-stage oncology company, has started a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia.

Clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of developing a breakthrough to traditional therapies by its novel drug candidates that have shown great promise in the treatment of a range of canc...

Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing cancer. The company’s mainstream operations are foc...

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations t...